ClinicalTrials.gg
CompletedNCT04139798Updated Oct 23, 2024Results posted

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

A Phase 3 interventional study of NOV03 and Placebo in Dry Eye Disease (DED), sponsored by Bausch & Lomb Incorporated. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
599
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.

Enrollment
2nd of 13
599 · median 216
Started
2020
with 2 others
Phase 3
4 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
9 of 13
Bausch & Lomb Incorporated

Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one is the 2nd largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About perfluorohexyloctane

perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF ( Form)
  • Subject-reported history of Drye Eye Disease (DED) in both eyes
  • Ability and willingness to follow instructions, including participation in all study assessments and visits

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, nursing or planning pregnancy
  • Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of , or unwillingness to use acceptable means of
  • slit-lamp findings or abnormal lid anatomy at screening and Visit 1
  • Ocular/peri-ocular
  • History of herpetic keratitis
  • Active ocular allergies or ocular allergies that are expected to be active during the study
  • Ongoing ocular or systemic infection
  • Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study
  • Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period
  • Presence of uncontrolled systemic diseases
  • Presence of known allergy and/or sensitivity to the study drug or saline components
  • Use of any topical treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
599 participants (actual)

Study arms

  • Experimental
    NOV03 4 times daily (QID)

    100% Perfluorohexyloctance solution 4 times daily (QID)

    Drug: NOV03

  • Placebo comparator
    Placebo 4 times daily (QID)

    Saline solution (0.6% sodium chloride solution) 4 times daily (QID)

    Drug: Placebo

Interventions

  • DrugNOV03

    100% Perfluorohexyloctane

  • DrugPlacebo

    Saline solution (0.6% sodium chloride solution)

06

What researchers measure

Primary outcomes

  1. Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57

    Corneal Fluorescein Staining (tCFS) is graded based on the NEI scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining, 3 corresponds to maximum staining. The total score is the sum of the 5 subregions ranging from 0-15.

    Time frame: Assessed from Baseline to Day 57

  2. Change From Baseline of Dryness Score at Day 57

    Dryness Score is rated on a visual analogue scale (VAS) ranging from 0-100; 0 corresponds to no discomfort and 100 to maximum discomfort).

    Time frame: Assessed from Baseline to Day 57

07

Results

Posted Oct 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneNOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)
Started303294
Completed289279
Not completed1415
Withdrew: Withdrawal by subject65
Withdrew: Lost to follow-up25
Withdrew: Discontinued42
Withdrew: Adverse event13
Withdrew: Protocol violation10

Outcome measures

PrimaryChange From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57

Corneal Fluorescein Staining (tCFS) is graded based on the NEI scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining, 3 corresponds to maximum staining. The total score is the sum of the 5 subregions ranging from 0-15.

Time frame:
Assessed from Baseline to Day 57
Reported as:
Mean · units on a scale
Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57
units on a scaleNOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)
Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57-2.0 ± 2.6-1.0 ± 2.7
PrimaryChange From Baseline of Dryness Score at Day 57

Dryness Score is rated on a visual analogue scale (VAS) ranging from 0-100; 0 corresponds to no discomfort and 100 to maximum discomfort).

Time frame:
Assessed from Baseline to Day 57
Reported as:
Mean · units on a scale
Change From Baseline of Dryness Score at Day 57
units on a scaleNOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)
Change From Baseline of Dryness Score at Day 57-27.4 ± 27.9-19.7 ± 26.7

Adverse events

Collected over Assessed throughout the study, approximately 8 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NOV03 4 Times Daily (QID)0/303 (0%)0/303 (0%)16/303 (5.3%)
Placebo 4 Times Daily (QID)0/294 (0%)0/294 (0%)11/294 (3.7%)
Most frequent other events
Most frequent other events
EventNOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)
Vision blurredEye disorders9/3031/294
Conjunctival haemorrhageEye disorders1/3034/294
Instillation site painEye disorders3/3033/294
Punctate keratitisEye disorders0/3033/294
Eye dischargeEye disorders3/3030/294

Baseline characteristics

Age, Continuous
Age, Continuous(years)NOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)Total
Mean60.3 ± 14.2361.6 ± 13.5760.9 ± 13.91
Sex: Female, Male
Sex: Female, Male(Participants)NOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)Total
Female219214433
Male8480164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NOV03 4 Times Daily (QID)Placebo 4 Times Daily (QID)Total
Hispanic or Latino435194
Not Hispanic or Latino260243503
Unknown or Not Reported000
08

Study locations

29 sites
  • Bausch Site 124
    Birmingham, Alabama 35233, United States
  • Bausch Site 125
    Scottsdale, Arizona 85254, United States
  • Bausch Site 110
    Glendale, California 91204, United States
  • Bausch Site 121
    Long Beach, California 90805, United States
  • Bausch Site 102
    Mission Hills, California 91345, United States
  • Bausch Site 101
    Newport Beach, California 92663, United States
  • Bausch Site 116
    Rancho Cordova, California 95670, United States
  • 103
    Torrance, California 90505, United States
  • Bausch Site 123
    Torrance, California 90505, United States
  • Bausch Site 127
    Danbury, Connecticut 06810, United States
  • Bausch Site 129
    Fort Myers, Florida 33901, United States
  • Bausch Site 115
    Jacksonville, Florida 32256, United States
  • Bausch Site 106
    Largo, Florida 33773, United States
  • Bausch Site 117
    Tampa, Florida 33603, United States
  • Bausch Site 108
    Lake Villa, Illinois 60046, United States
  • Bausch Site 112
    Indianapolis, Indiana 46260, United States
  • Bausch Site 119
    Edgewood, Kentucky 41017, United States
  • Bausch Site 126
    Winchester, Massachusetts 01890, United States
  • Bausch Site 113
    Kansas City, Missouri 64111, United States
  • Bausch Site 111
    Saint Louis, Missouri 63131, United States
  • Bausch Site 128
    Slingerlands, New York 12159, United States
  • Bausch Site 114
    Raleigh, North Carolina 27603, United States
  • Bausch Site 122
    Cranberry Township, Pennsylvania 16066, United States
  • Bausch Site 107
    Memphis, Tennessee 38119, United States
  • Bausch Site 109
    Nashville, Tennessee 37205, United States
  • Bausch Site 120
    El Paso, Texas 79902, United States
  • Bausch Site 104
    Lakeway, Texas 78738, United States
  • Bausch Site 105
    Round Rock, Texas 78681, United States
  • Bausch Site 118
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2021, 7 months.

Results were first posted in Oct 2024, 3 years 7 months after primary completion. A results delay was requested in Mar 2022.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Oct 25, 2019
StartActual
Jul 20, 2020
Primary completionActual
Mar 12, 2021
CompletionActual
Mar 12, 2021
Results delay requested
Mar 11, 2022
Results first posted
Oct 23, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04139798
Responsible party
Sponsor
First posted
Oct 25, 2019
Start date
Jul 20, 2020
Primary completion
Mar 12, 2021
Completion
Mar 12, 2021
Results posted
Oct 23, 2024
Last update
Oct 23, 2024

Study contacts

Johnson Varughese
study director · Bausch Health

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perfluorohexyloctane

Start the discussion